Luulyo 2022: On July 12, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and ACT Therapeutics (Seogkyoung-Kong, CEO), developing a next-generation chimeric antigen receptor (CAR)-T cell therapy platform targeting solid cancer, announced that they had entered into a strategic partnership MOU concerning the development of a new CAR-T cell therapies. The MOU was in regard to the development of new CAR-T cell therapies. Through the use of this memorandum of understanding (MOU), GenScript ProBio and ACT Therapeutics have come to an agreement to further their collaboration in the field of cell therapy.
ACT Therapeutics iyo GenScript ProBio waxay ku guda jiraan saxeexa qandaraaska horumarinta iyo soo saarista fayraska plasmid iyo fayraska ee dhuumaha ugu horreeya ee ACT Therapeutics' Advanced CAR-T Platform (ACT platform), kaas oo sidoo kale loo wakiishay inuu soo saaro alaabta ceeriin. ee dhuumaha xiga ee ACT Therapeutics. Qandaraasku wuxuu dabooli doonaa soo saarista plasmids iyo fayraska fayraska ee dhuumaha ugu horreeya ee ACT Therapeutics ' Advanced CAR-T Platform.
Natiijadii heshiiskan, GenScript ProBio waxaa sare loogu qaaday heerka lammaane caalami ah oo awood u leh inuu taageero aaladaha ACT ee daaweynta ACT.
Qalabka ACT waa unug soo socda iyo tignoolajiyada daaweynta hidda-wadaha kaas oo bartilmaameedsada antigens-ka kansarka iyada oo la gelinayo hiddo-wadaha loogu talagalay in lagu beegsado antigen-yada unugyada difaaca. Hidde-sidayaashan waxa la geeyaa unugyo difaaca iyada oo la adeegsanayo fayraska. GenScript ProBio waxa uu leeyahay horumar habka fayraska tayada sare leh iyo goob adeeg hal-joojin ah oo loogu talagalay soosaarka GMP, oo labaduba lagama maarmaan u ah horumarinta unugyada iyo daaweynta hidda-wadaha.
ACT Therapeutics’ ACT platform is an advanced CAR-T technology that has a next-generation structure that goes beyond the second-generation CAR-T cell therapy and targets existing kansarka dhiigga. This is accomplished by overcoming the immune suppression microenvironment of solid cancer and activating the immune cells that are surrounding the cancer. Several studies have also used animals to test the ACT platform to see how well it works and if it is safe. These studies have also confirmed that the platform can be used to treat solid cancer while staying in the immunosuppressive environment of that cancer. Additionally, it complements the shortcomings of the existing second-generation CAR-T, which makes it a competitive technology for the treatment of solid cancer.
ACT Therapeutics is a Korean bio venture company that has received initial investment through DAYLI Partners, Korea’s leading bio and healthcare venture capital, since its establishment in 2020, and has been recognized for its technology such as receiving pre-series A investment in Samho Green Investment. DAYLI Partners is Korea’s leading bio and healthcare venture capital since its establishment in 2020. At the moment, investment consultations are being held with various securities firms and venture capital companies in order to entice Series A investment.
Brian H. Min, CEO of GenScript ProBio, said, “We are very happy to cooperate with ACT therapeutics in strategic partnership, and we are looking forward to support ACT Therapeutics’ ACT platform as a global partner through our accumulated technology.”
Seogkyoung-Kong, oo ah maamulaha guud ee ACT Therapeutics, ayaa yiri, "Waxaan dhameeystirnay u diyaar garowga ACT madal si ay uga soo baxdo caalami ahaan iyada oo loo marayo iskaashi istiraatiiji ah oo lala yeesho GenScript ProBio. Waxaan dardargelin doonnaa horumarinta daawaynta lagu beegsanayo kansarrada adag ee aan la daweyn karin.
Ku saabsan GenScript ProBio
GenScript ProBio is a subsidiary of GenScript Biotech Corporation, proactively providing end-to-end CDMO service from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in cell and gene therapy (CGT), vaccine discovery, biologics discovery and antibody protein drug development to accelerate drug development for customers. GenScript ProBio has established companies in the United States, the Netherlands, South Korea, Shanghai, Hong Kong, Nanjing and other places to serve global customers, and supported customers in the United States, Europe, Asia Pacific and other regions to obtain more than 30 IND approvals.
Dhanka himilada "hal-abuurnimo iyada oo loo marayo iskaashiga", GenScript ProBio waxaa ka go'an inay ka caawiso macaamiisha inay soo gaabiyaan wakhtiga horumarinta dawooyinka noolaha laga bilaabo daahfurka ilaa ganacsi, hoos u dhigista kharashka R&D iyo dhisida mustaqbal caafimaad leh.
